Payment overview · 2025
General Payments
$435.97
23 reported records · 17 companies
Healthcare provider profile · identity verified
Frank L Carter, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · AUGUSTA, GA · NPI 1164464087
Verified facts
What the public records show
CMS Open Payments records show Frank L Carter, M.D. received $435.97 in general payments during 2025 across 23 reported records.
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) accounted for 14.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 25 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Mounjaro.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Myrbetriq by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Xtandi as an associated drug or biological on 11345 records involving 5418 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Xtandi by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Farxiga by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 68 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 57 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $63.78 | 14.6% | 4 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $59.41 | 13.6% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $33.50 | 7.7% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $32.68 | 7.5% | 2 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $29.93 | 6.9% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $28.10 | 6.5% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $27.78 | 6.4% | 1 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $18.75 | 4.3% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $17.65 | 4.0% | 1 | 2025 |
| Seqirus USA Inc | Unresolved — no canonical attribution shown | $17.38 | 4.0% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $16.89 | 3.9% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $16.88 | 3.9% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $16.54 | 3.8% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $14.31 | 3.3% | 1 | 2025 |
| SANOFI PASTEUR INC. | Unresolved — no canonical attribution shown | $14.27 | 3.3% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $14.16 | 3.2% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $13.96 | 3.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $435.97 | 23 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $63.78 | 4 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $59.41 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $33.50 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $32.68 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $32.68 | 2 | 2025 |
Source payment records
|
|||||
| WaveWriter Alpha Prime 16 Normalized: wavewriter alpha prime 16 |
Device | Boston Scientific Corporation | $29.93 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $28.10 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $27.78 | 1 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $18.75 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $17.65 | 1 | 2025 |
Source payment records
|
|||||
| Fluad Normalized: fluad |
Biological | Seqirus USA Inc | $17.38 | 1 | 2025 |
Source payment records
|
|||||
| Flucelvax Normalized: flucelvax |
Biological | Seqirus USA Inc | $17.38 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $16.89 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $16.89 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $16.88 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $16.54 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $14.31 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $14.31 | 1 | 2025 |
Source payment records
|
|||||
| BEYFORTUS Normalized: beyfortus |
Biological | SANOFI PASTEUR INC. | $14.27 | 1 | 2025 |
Source payment records
|
|||||
| FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE Normalized: flublok quadrivalent northern hemisphere |
Biological | SANOFI PASTEUR INC. | $14.27 | 1 | 2025 |
Source payment records
|
|||||
| FLUZONE HIGH-DOSE Normalized: fluzone high dose |
Biological | SANOFI PASTEUR INC. | $14.27 | 1 | 2025 |
Source payment records
|
|||||
| VAXELIS Normalized: vaxelis |
Biological | SANOFI PASTEUR INC. | $14.27 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $14.16 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $13.96 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $13.96 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 25 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Xtandi open payments reported associated product |
CMS Open Payments — General Payments 11345 supporting records · 5418 recipient NPIs · example record 1238560686 |
Xtandi · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
68 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
44 | 13 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
57 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 424 | 120 |
| Amlodipine Besylate | Amlodipine Besylate | 413 | 122 |
| Metformin Hcl Er | Metformin Hcl | 218 | 62 |
| Omeprazole | Omeprazole | 204 | 63 |
| Levothyroxine Sodium | Levothyroxine Sodium | 203 | 56 |
| Furosemide | Furosemide | 190 | 56 |
| Potassium Chloride | Potassium Chloride | 189 | 48 |
| Losartan Potassium | Losartan Potassium | 188 | 53 |
| Gabapentin | Gabapentin | 173 | 46 |
| Pravastatin Sodium | Pravastatin Sodium | 164 | 43 |
| Eliquis | Apixaban | 149 | 29 |
| Metformin Hcl | Metformin Hcl | 134 | 38 |
| Lisinopril | Lisinopril | 131 | 41 |
| Carvedilol | Carvedilol | 120 | 31 |
| Diclofenac Sodium | Diclofenac Sodium | 115 | 38 |
| Donepezil Hcl | Donepezil Hcl | 114 | 35 |
| Hydrochlorothiazide | Hydrochlorothiazide | 114 | 31 |
| Metoprolol Succinate | Metoprolol Succinate | 108 | 33 |
| Pantoprazole Sodium | Pantoprazole Sodium | 105 | 27 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 100 | 27 |
| Glipizide | Glipizide | 96 | 24 |
| Ibuprofen | Ibuprofen | 93 | 31 |
| Famotidine | Famotidine | 92 | 28 |
| Meloxicam | Meloxicam | 91 | 24 |
| Atenolol | Atenolol | 89 | 28 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 88 | 30 |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 88 | 31 |
| Tamsulosin Hcl | Tamsulosin Hcl | 85 | 31 |
| Benazepril Hcl | Benazepril Hcl | 84 | 21 |
| Metoprolol Tartrate | Metoprolol Tartrate | 84 | 24 |
| Temazepam | Temazepam | 84 | 21 |
| Tizanidine Hcl | Tizanidine Hcl | 84 | 42 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 76 | 27 |
| Jardiance | Empagliflozin | 68 | 11 |
| Simvastatin | Simvastatin | 68 | 19 |
| Hydralazine Hcl | Hydralazine Hcl | 66 | 20 |
| Sertraline Hcl | Sertraline Hcl | 66 | 21 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 65 | 20 |
| Januvia | Sitagliptin Phosphate | 62 | 14 |
| Montelukast Sodium | Montelukast Sodium | 62 | 18 |
| Zolpidem Tartrate | Zolpidem Tartrate | 62 | 13 |
| Chlorthalidone | Chlorthalidone | 61 | 21 |
| Pioglitazone Hcl | Pioglitazone Hcl | 61 | 14 |
| Prednisone | Prednisone | 61 | 37 |
| Rybelsus | Semaglutide | 57 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 55 | 19 |
| Tramadol Hcl | Tramadol Hcl | 54 | 24 |
| Pregabalin | Pregabalin | 53 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 50 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 49 | 14 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 49 | 33 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 47 | 34 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 46 | 15 |
| Glimepiride | Glimepiride | 45 | 11 |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 44 | suppressed |
| Ezetimibe | Ezetimibe | 44 | suppressed |
| Ozempic | Semaglutide | 44 | 13 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 42 | 11 |
| Escitalopram Oxalate | Escitalopram Oxalate | 42 | 17 |
| Azithromycin | Azithromycin | 41 | 36 |
| Memantine Hcl | Memantine Hcl | 40 | 14 |
| Dutasteride | Dutasteride | 39 | suppressed |
| Glipizide Er | Glipizide | 38 | 12 |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 38 | suppressed |
| Celecoxib | Celecoxib | 37 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 37 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 35 | 22 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 35 | 12 |
| Allopurinol | Allopurinol | 33 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 33 | 13 |
| Oxybutynin Chloride | Oxybutynin Chloride | 33 | 13 |
| Indapamide | Indapamide | 32 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 32 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 32 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 31 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 31 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 31 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 30 | 15 |
| Alprazolam | Alprazolam | 29 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 29 | suppressed |
| Naproxen | Naproxen | 29 | 16 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 28 | 19 |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 28 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 28 | suppressed |
| Nuplazid | Pimavanserin Tartrate | 28 | suppressed |
| Sucralfate | Sucralfate | 28 | 13 |
| Cefuroxime | Cefuroxime Axetil | 27 | 27 |
| Ondansetron Hcl | Ondansetron Hcl | 27 | 23 |
| Clonazepam | Clonazepam | 26 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 25 | suppressed |
| Levetiracetam | Levetiracetam | 25 | suppressed |
| Mounjaro | Tirzepatide | 25 | suppressed |
| Valsartan | Valsartan | 25 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 24 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 24 | 15 |
| Mirtazapine | Mirtazapine | 24 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 24 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 23 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 23 | 14 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 23 | 20 |
| Doxycycline Hyclate | Doxycycline Hyclate | 22 | 18 |
| Farxiga | Dapagliflozin Propanediol | 22 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 22 | suppressed |
| Diazepam | Diazepam | 21 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 21 | suppressed |
| Spironolactone | Spironolactone | 21 | suppressed |
| Amoxicillin | Amoxicillin | 20 | 18 |
| Nifedipine Er | Nifedipine | 20 | suppressed |
| Synthroid | Levothyroxine Sodium | 20 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 19 | suppressed |
| Bupropion Xl | Bupropion Hcl | 19 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Nystatin | Nystatin | 19 | 12 |
| Primidone | Primidone | 19 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 19 | suppressed |
| Fluconazole | Fluconazole | 18 | 12 |
| Sumatriptan Succinate | Sumatriptan Succinate | 18 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 17 | 17 |
| Myrbetriq | Mirabegron | 17 | suppressed |
| Creon | Lipase/Protease/Amylase | 16 | suppressed |
| Estradiol | Estradiol | 16 | suppressed |
| Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 16 | suppressed |
| Linzess | Linaclotide | 15 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 15 | suppressed |
| Finasteride | Finasteride | 14 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 14 | 14 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 13 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 13 | suppressed |
| Ramipril | Ramipril | 13 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 13 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 13 | suppressed |
| Xarelto | Rivaroxaban | 13 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 12 | suppressed |
| Calcium Acetate | Calcium Acetate | 12 | suppressed |
| Entresto | Sacubitril/Valsartan | 12 | suppressed |
| Fenofibrate | Fenofibrate | 12 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 12 | suppressed |
| Ketoconazole | Ketoconazole | 12 | suppressed |
| Lacosamide | Lacosamide | 12 | suppressed |
| Levemir | Insulin Detemir | 12 | suppressed |
| Metronidazole | Metronidazole | 12 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 12 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 12 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 11 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 11 | suppressed |
| Humalog | Insulin Lispro | 11 | suppressed |
| Hydrocortisone | Hydrocortisone | 11 | suppressed |
| Klor-Con M10 | Potassium Chloride | 11 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 11 | suppressed |
| Xtandi | Enzalutamide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $435.97 · 23 records | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Auvelity, BEYFORTUS, CAPLYTA, CAPVAXIVE, FANAPT, FARXIGA, FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE, FLUZONE HIGH-DOSE, FREESTYLE LIBRE 3, Fluad, Flucelvax, GARDASIL 9, Kerendia, MOUNJARO, OTEZLA, QULIPTA, REPATHA, REXULTI, UBRELVY, VAXELIS, Veozah, WaveWriter Alpha Prime 16, Wegovy, XIFAXAN, ZEPBOUND | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error